NCT01346540 - A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 14, 2011

Primary Completion Date

April 25, 2013

Study Completion Date

January 17, 2017

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

BIBF 1120

VEGF inhibitor

DRUG

Placebo

BIBF 1120 placebo

Trial Locations (7)

1199.82.39004 Boehringer Ingelheim Investigational Site, Milan

1199.82.3102 Boehringer Ingelheim Investigational Site, Maastricht

1199.82.3401 Boehringer Ingelheim Investigational Site, Barcelona

1199.82.3406 Boehringer Ingelheim Investigational Site, Madrid

1199.82.3410 Boehringer Ingelheim Investigational Site, Málaga

1199.82.4401 Boehringer Ingelheim Investigational Site, London

1199.82.4402 Boehringer Ingelheim Investigational Site, Manchester